About Us

ArcherDX, Inc. is a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine.

Using next-generation sequencing (NGS) technology, Archer® offers a robust platform for detecting variants associated with cancers and inherited diseases.

By using proprietary Anchored Multiplex PCR (AMP™) chemistry, Archer technology has robust detection capabilities for all variant types. Complemented by a suite of bioinformatics software, the Archer platform dramatically enhances complex variant identification and discovery.

ArcherDX provides oncology-focused research panels, formed by 4 product lines: FusionPlex®, VariantPlex®, LiquidPlex™ and Immunoverse™.

ArcherDX, Inc. is headquartered in Boulder, Colorado.

Where ArcherDX Fits In
ArcherDX Fast Facts
>200
Customers Across
45+ Countries Use Archer Panels
>300
Custom Assays
>365
Posters & Peer Reviewed Publications

Leadership

The ArcherDX, Inc. leadership team is dedicated to leading the transformation to personalized medicine in oncology by empowering physicians to apply high-quality genomic data in daily clinical care.

Jason Myers
President & Chief Executive Officer
Josh Stahl
Executive Vice President & Chief Scientific Officer
Matt Franklin
Chief Business Officer
Christian LaPointe
Deputy General Counsel
Aaron Berlin
Vice President, Bioinformatics & Commercial Software
Nancy Casey
Vice President, Accounting & Finance
Ryan Walters
Vice President, Assay Development & Scientific Operations
Board of Directors

Paul Manning
President & Chief Executive Officer,
PBM Capital Group

Steve Kafka
Executive Chairman, Board of Directors

Kyle Lefkoff
Founder & Partner,
Boulder Ventures Ltd.

Jason Myers
Co-founder & Chief Executive Officer,
ArcherDX, Inc.

Marvin H. Caruthers
Distinguished Professor,
University of Colorado Boulder

Scientific Advisors

John Iafrate
ArcherDX, Inc. Co-founder, Pathologist & Medical Director for the Center for Integrated Diagnostics,
Massachusetts General Hospital

Long Phi Le
ArcherDX, Inc. Co-founder, Director of Technology & Development Center for Integrated Diagnostics & Director of Computational Pathology,
Massachusetts General Hospital

Bob Daber
President & Chief Technology Officer,
Genosity

Alexander Lazar
Professor, Director of the Selective (Soft Tissue) Pathology Fellowship Training Program & Director of the Sarcoma and Melanoma Clinical Genomics Program,
MD Anderson Cancer Center

​Jason Myers
President & Chief Executive Officer

 Jason Myers is a co-founder of ArcherDX, Inc. and currently serves as chief executive officer.

With over 20 years of experience in the biotech industry, Dr. Myers has established a track record of successful technology development and enterprise value creation. Prior to founding ArcherDX, Dr. Myers led cross-functional platform and sequencing application development for Ion Torrent™ where his leadership contributed to the $725 million-dollar acquisition of Ion Torrent™ by Life Technologies in 2010. In addition, Dr. Myers discovered and successfully licensed a first of its kind loss-of-function RNAI screening product to leading molecular chemistry companies including Ambion, Invitrogen, Roche, Stratagene and UBS.

Dr. Myers received his Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and a Bachelor of Applied Science from Colorado State University.

Josh Stahl
Executive Vice President & Chief Scientific Officer

Josh Stahl is the executive vice president and chief scientific officer of ArcherDX. Josh joined ArcherDX, Inc. in 2013, guiding the company’s product portfolio first as director of NGS research and development and scientific operations and later as vice president of research and development. In 2016, Josh expanded his role, assuming responsibility for ArcherDX’s operational functions.

Prior to joining ArcherDX, Josh was a scientist at Thermo Fisher Scientific where he worked on the company’s gene modulation portfolio developing siRNA and shRNA NGS-based screening methods.

Josh holds a bachelor’s degree in Biochemistry and Molecular Biology from West Virginia University. He attended graduate school at the University of Colorado, Boulder where he earned both a master’s degree in Biochemistry and a Master of Business Administration degree in Entrepreneurship.

Matt Franklin
Chief Business Officer

Matt Franklin joined ArcherDX, Inc. in August 2018 as chief business officer. He brings a diverse set of skills to ArcherDX, Inc. with more than 20 years of experience in global marketing, product development, corporate strategy, business development and program management roles across a variety of healthcare and technology sectors. In each of these roles, Matt has established a track record of accelerating business growth and building high-performing teams.

Prior to joining ArcherDX, Matt was senior vice president of global marketing and clinical product strategy for Foundation Medicine, leading the global commercialization of their clinical diagnostic portfolio including the company’s first liquid biopsy assay and the first FDA approved pan-tumor companion diagnostic. Before this, Matt was vice president of global marketing at Boston Scientific where he was a member of the interventional cardiology leadership team and responsible for product strategy and global commercialization activities for a diverse portfolio of products generating over $2B in annual revenues. Earlier in his career, he was a consultant in the cross-industry technology practice at Accenture.

Matt has a bachelor’s degree from Northwestern University in Evanston, IL and a Master of Business Administration degree from the University of Michigan, Ann Arbor.

Christian LaPointe
General Counsel

Dr. Christian LaPointe has served as general counsel for ArcherDX, Inc. since 2013, contributing his extensive expertise in intellectual property portfolio creation, licensing, agreement negotiations, employment, and corporate matters developed over the course of his work at multiple early stage life science companies and law firms.

Prior to joining ArcherDX, Dr. LaPointe served in the general counsel office for the Dana-Farber Cancer Institute, where he managed the patent portfolio and was involved in launching multiple companies including Aileron Therapeutics, Metamark Genetics, Acetylon Pharmaceuticals (acquired by Celgene), and Genus Oncology. During his law firm career his practice areas included patent prosecution and litigation, FTO analysis, and trade secret misappropriation disputes for clients such as Boston Scientific, MIT, Harvard and Exact Sciences. Dr. LaPointe has served as general counsel for life science companies Enzymatics and Thrive Bioscience.

Dr. LaPointe received a Ph.D. in Biochemistry from Dartmouth Medical School, where his thesis work led to multiple issued patents, and a Bachelor of Science in Biochemistry with high honors from the University of New Hampshire. He earned a JD from Suffolk Law School with a concentration in intellectual property.

Aaron Berlin
Vice President, Bioinformatics & Commercial Software

Aaron Berlin is the vice president of bioinformatics and commercial development at ArcherDX. Aaron joined the team in 2014 as a bioinformatics scientist and has contributed to the development of the Archer® Analysis and Archer® Quiver® products.

Prior to joining Archer, Aaron worked at the Broad Institute in the Genome Sequencing and Analysis Program and Broad Technology Labs. There he evaluated new sequencing technologies and contributed to the sequencing and assembly of numerous organisms ranging from viruses to mammals.

Aaron received his undergraduate and Masters degree from Boston University.

Nancy Casey
Vice President, Accounting & Finance

Nancy Casey joined ArcherDX, Inc. as vice president of finance & accounting in April 2018.

An accomplished accounting-finance executive, Nancy brings extensive experience in multinational, multi-location companies in the life science, high tech, telecommunications, retail and manufacturing industries. Her background includes Securities & Exchange Commission filings including initial public offerings, Sarbanes-Oxley compliance, mergers and acquisitions, and leading the accounting, finance, tax and payroll functions to support business strategy and operations. Prior to joining Archer, Nancy was the controller of Sequel Venture Partners, a $400 million venture capital firm focused on early-stage investing in life science and information technology start-up companies. She also was the corporate controller at Intrado, Inc., a $140 million public, global provider of public safety telecommunications software and services. Nancy previously served as the corporate controller and treasurer at the publicly traded Wild Oats Markets, Inc., during which time the company grew from eight stores in two states with $38 million in revenue to 101 stores in 25 states and British Columbia with $900 million in revenue. Earlier in her career, Nancy was an audit manager for middle market and growing companies at Price Waterhouse, LLP, serving the entrepreneurial technology product market.

Nancy is an actively-licensed certified public accountant in the State of Colorado and is a member of the American Institute of Certified Public Accountants and the Colorado Society of Certified Public Accountants. She holds a bachelor’s degree in Biology and a master’s degree in Accounting from the University of Colorado, Boulder.

Ryan Walters
Vice President, Assay Development & Scientific Operations

Dr. Ryan Walters is the vice president of assay development and scientific operations at ArcherDX. Ryan oversees the development of catalog and custom assays utilizing Archer’s AMP™ technology. His team is responsible for delivering innovative, high quality assays for use in oncology, immunology and hereditary conditions.

Prior to leading Assay Development at ArcherDX, Dr. Walters created the custom assay development capability at ArcherDX, recruiting a team and deploying a scalable solution to rapidly deliver customized assays for use with RNA, DNA or blood-based circulating tumor DNA.

Dr. Walters holds a Ph.D. in Biochemistry from the University of Colorado, Boulder and a Bachelor of Science in Biochemistry from Colorado State University in Fort Collins.

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.